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CHARACTERIZATION OF BK VIRAL RESPONSES TO THE DUAL-
PI3K/mTOR INHIBITOR DACTOLISIB (NVP BEZ-235) IN A RENAL CELL 
CULTURE MODEL 
GABRIEL BENJAMIN WARACH LERNER 
ABSTRACT 
BK virus (BKV) is a ubiquitous polyomavirus known to asymptomatically reside 
in the renal tissues of up to 90% of the human population. BK virions reactivate during 
periods of intense immunosuppression and can cause disease in renal transplant recipients, 
such as BKV-associated nephropathy (BKVAN). BKVAN can lead to loss of the 
transplanted renal grafts. For this reason, the study of BKV biology is of importance to the 
transplant community. Previous studies have shown that BKV upregulates the pro-growth 
mTOR pathway in host cells, thereby increasing BKV replicative efficiency. Downstream 
effectors of the mTOR pathway, particularly p70S6 kinase, control the basal rate of 
protein translation, in part through regulation of ribosomal biogenesis. It was hypothesized 
that viral upregulation of the mTOR pathway is beneficial for viral replication due to an 
increase in the number of ribosomes available to translate viral proteins. Therefore, 
inhibition of the mTOR pathway could reduce viral replication. This study investigated 
whether host cell mTOR inhibition could reduce BK viral replication in an in vitro model. 
We utilized the dual PI3K/mTOR inhibitor NVP BEZ-235 (Novartis Pharmaceuticals), 
which potently downregulates expression of both upstream (PI3K) and central (mTOR) 
effectors of the mTOR pathway.  
Immortalized renal epithelial cells were exposed to varying concentrations of 
BEZ-235 for a period of 48 hours, infected with BK virus for three hours, and allowed to 
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grow for a further 48 hours. Cell populations were then assayed via quantitative PCR 
(qPCR), Western blotting and fluorescent immunohistochemical staining to determine the 
effect of BEZ-235 on BK viral replication.  
Western blot experiments confirmed the effectiveness of BEZ-235’s inhibition of 
the mTOR pathway in a renal epithelial cell culture model, as well as downregulation of 
the mTOR pathway during BK viral infection. Western blotting for the key BK replicative 
protein Large T antigen, showed a dose-dependent decrease in expression, with increasing 
concentrations of BEZ-235. Fluorescent immunohistochemical staining showed a dose-
dependent decrease in expression of Large T antigen staining in host cell nuclei. qPCR 
results were inconclusive, in that no clear pattern in the number of BKV genomes per cell 
population could be observed across the range of BEZ-235 concentrations tested. 
While results from our study indicate that BEZ-235 can reduce BKV replication in 
vitro, further in vitro experimentation, including repetition of approaches already carried 
out as well as novel approaches, will be needed to definitively confirm inhibition of the 
mTOR pathway as a viable antiviral strategy.   
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INTRODUCTION 
Motivation for Study of the Polyomaviruses: SV40, JC virus, and BK virus 
 
Polyomaviruses are a diverse group of species-specific, non-enveloped, double-
stranded DNA viruses that are ubiquitous in nature (1). Some members of this family are 
thought to latently, asymptomatically infect a large percentage of humans (Table 1):  
 
Table 1. 	  Seroprevalence of known human polyomaviruses in healthy 
adults. ‘Seroprevalence’ refers to the proportion of samples in a 
population that are positive for serum antibodies against species-specific 
viral proteins, as a result of prior immune exposure. BKV is highlighted in 
red. Modified from Dalianis and Hirsch, 2013 (2). 	  
 
 
 
Although most polyomaviruses are thought to be clinically harmless, several have 
been implicated in disease. Simian Virus 40 (SV40) was the first non-human 
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polyomavirus to be isolated, after having been found in contaminated rhesus monkey 
renal cell cultures used to produce poliovirus vaccine (3). SV40 contamination was 
detected in both Salk (inactivated) and Sabin (live-attenuated) vaccines: it has been 
estimated that over 98 million people were exposed at the time (4). For the next several 
decades, the question of whether SV40 is capable of causing cancerous growth of human 
cells emerged as one of the most controversial in all of cancer research (4). Subsequent 
studies investigated the epidemiologic and transformative consequences of this mass 
contamination event, and concluded that there was insufficient evidence to suggest that 
the virus was oncogenic (4). These decades of intensive study, however, have shed much 
light on the biology, life cycle, and virulence mechanisms of Polyomaviruses in general.  
SV40 is also known as Simian Vacuolating virus, for the intracellular vacuoles 
that these virions induce internally in productively infected simian cells (3). Currently, 
strains of SV40 are used by researchers largely as a tool to create ‘immortalized’ cell 
lines. Pro-growth SV40-derived genes are artificially inserted into primary cell genomes, 
inducing them to grow indefinitely in proper culture conditions. While it has not been 
shown to induce disease in humans, SV40 remains the single most well-studied 
polyomavirus. Its attributes, viral lifecycle, and genomic structure have been used to 
inform the study of the biology of the more clinically relevant polyomaviruses: JC virus 
(JCV) and BK virus (BKV). In a very real way, the scientific lives of these latter viruses 
exist in the shadow of SV40, their more well-studied cousin.  
JCV was discovered in 1971 by Padgett et al., and eventually implicated as the 
etiologic agent of the rare and often fatal brain disease, progressive multifocal 
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leukoencephalopathy (PML) (5). BKV and JCV resides latently in the kidneys, bone 
marrow, and lymph nodes of healthy persons (6). Immunosuppressed states, such as those 
caused by chronic HIV infection, organ transplantation or the treatment of some cancers, 
permit JCV to reactivate within the oligodendrocytes of the central nervous system (7). 
Oligodendrocytes produce myelin sheath that wraps around neurons, enabling signal 
conduction in the CNS. Such selective tropism may cause localized immune system 
activation and formation of the foci that are characteristic of PML.  
PML-associated foci are small (typically 1-3 mm in diameter) distinct areas of 
demyelination that usually appear in the white matter of the brain (8). Lesions are 
necrotic in nature, and produced secondary to destruction of oligodendrocytes following 
lytic JCV infection (8). PML, as the name suggests, is a progressive disease – lesions that 
first appear as solitary entities may later become ‘clumped’ in groups and merge together 
over time (6). Recent studies suggest that JCV may also be capable of independently 
infecting the meninges covering the outer surface of the brain, as well as neurons in the 
granule cell layer of the cerebellum and pyramidal neurons in the cortex (9, 10). Such 
tropic infections cause ‘JCV-Meningitis’ (JCV-M), ‘JC Virus Granular Cell 
Neuronopathy’ (JCV-GCN) and ‘JC Virus Encephalopathy’ (JCV-E), respectively (9-11). 
Further studies are needed to elucidate the molecular mechanisms responsible for the 
tropism of JC virus to these distinct cell types, as well as the full implications of such 
tropism on the clinical presentations and syndromes observed in patients with JC virus-
associated pathology.  
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In the past decade, the introduction of novel genetic sequencing techniques has 
led to the discovery of many other members of the Polyomavirus family. These include 
Merkel cell polyomavirus (MCPyV), which has been implicated in the pathogenesis of 
Merkel Cell Carcinoma, KIPyV and WUPyV (named after the institutions where they 
were discovered; the Karolinska Institute in Stockholm, Sweden, and Washington 
University in St. Louis, respectively), and the rationally named Human Polyomaviruses 
6, 7, and 9, among others (2). Viral genotypic analyses have confirmed a high degree of 
sequence similarity between BK, JC, and SV40 viruses, implying close common ancestry 
as well as shared growth, infection, and virulence mechanisms (Figure 1; (12)).  
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Figure 1. Phylogenetic analysis of the evolutionary relationships among 
members of Polyomaviridae.  Malawi Polyomavirus (MWPyV), a newly 
discovered polyomavirus originating in Malawi, is bolded, and the clade 
containing BKV, JCV, and SV40 is outlined in red. BKV, JCV, and SV40 
share a high degree of sequence homology. Amino-acid based 
phylogenetic trees were generated using the maximum likelihood method, 
with 1,000 bootstrap replicates. A) represents relationships determined via 
VP1 sequence, B) via VP2 sequence, and C) via Large T antigen 
sequence. Figure modified from Siebrasse, et al., 2012 (12).  
 
Discovery and Characterization of BK Virus 
 
BKV is a double-stranded, non-enveloped, human DNA polyomavirus with an 
icosahedral capsid 40 – 44 nm in diameter. It has a genome of approximately 5,200 base 
pairs and was first isolated from virally infected cells in the urine of a renal transplant 
recipient (initials ‘BK’), in London in 1970 (13). These cells were examined via light and 
electron microscopy, and found to exhibit enlarged, activated nuclei, with high 
concentrations of viral particles (Figures 2, 3; (14)). Subsequent cellular culturing 
confirmed the presence of the virus (14).  
 
‘Ground-­‐	  Glass’	  type	  viral	  nuclear	  inclusion	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Figure 2. Light microscopy image of urinary ‘decoy cells’ containing 
BKV. ‘N,’ nucleus; ‘C,’ cytoplasm; 400x magnification. Note the 
enlarged nucleus (greater than average nucleus to cytoplasmic ratio) and 
‘ground-glass’ appearance, indicative of viral stimulation of host cell 
transcription and translation. Visualized with the Papanicolaou stain. 
Image modified from Ashan, 2006 (15).  
 
 
Figure 3. Electron microscopy images of BKV-infected renal epithelial cells. 
Figure 1A shows BK virions isolated from the urine of patient ‘BK.’ Figure 1B 
shows two renal epithelial cells in a nephron (‘L’ shows the nephron luminal 
space), with significant viral inclusions (‘V’) found within the cell nuclei (‘N’); 
corner inset of this image shows clusters of BK virions. Figure 1A is 180,000x; 
Figure 1B is 6000x, and inset is 22,500x. Figures modified from (Gardner, et al., 
1971), with permission from the publisher (16).  
 
Since its discovery, BKV has been implicated as an important human pathogen 
that causes disease in immunosuppressed populations including: transplant recipients, 
patients undergoing chemotherapy, and those infected with Human Immunodeficiency 
Virus (HIV). 
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Primary BK Infection  
 
BKV is virtually ubiquitous in man; some 70 – 99 % of the world’s human 
population is thought to be latently infected (2, 14). In fact, by tracking the evolution and 
mutational status of BKV strains in contemporary human populations across the globe, 
scientists have been able to confirm and substantiate early human migratory patterns (17). 
Primary infection with BKV occurs asymptomatically during infancy or early childhood, 
through the oral route. Although the initial acquisition of this virus is poorly understood, 
mechanisms of transmission are presumed to be through environmental, respiratory, 
urinary, or vertical (maternal to fetal) means (18, 19). The first site of invading BK virus 
populations may be in the tonsillar tissue, followed by trafficking to the kidneys via 
infection of peripheral blood mononuclear cells (PBMCs) that circulate through the 
secondary immune tissues of the tonsils (20, 21).  
As a nephrotropic virus, BKV homes to, and establishes latency within, the 
epithelial cells of the kidney and genitourinary tract (22). BK viral latency is defined by 
quiescence; the virus persists inside the host cell without attempt to replicate itself. Latent 
BKV can exist in the body for the entire life of the individual, without progression to 
viral reactivation or disease. The BK viral genome exists in an episomal form in the 
nucleus of human cells, although it has been shown to incorporate itself into the host 
genomes of some rodent cell lines (20).  
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BK Virus Genome and Viral Proteins 
 
The BK viral genome is circular, double-stranded, and approximately 5,100 base 
pairs in length, with six well-defined protein encoding genes and a non-coding regulatory 
region (Figure 4; (20)):  
 
 
 
Figure 4. Genomic map of BK virus, Dunlop strain. Approximate 
genome length: 5,153 base pairs; transcribed in both directions from the 
origin of replication (‘ori;’ green), via a temporally-regulated mechanism 
(not simultaneously). The origin of replication is located within the 
noncoding regulatory region (NCRR; green). Large and small t antigen (in 
blue) are the so-called ‘early genes,’ which are transcribed and translated 
early in the viral life cycle. VP1, VP2, and VP3 (in red) are the ‘late 
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genes,’ which code for BK capsid proteins. The function of BK 
agnoprotein (purple) is currently under study, but the protein may be 
involved in nuclear localization of maturing virions, and release of viral 
progeny during lytic episodes (41). Figure modified from Cubitt, et al., 
2013 (20). 
 
Like all polyomaviruses, the BK viral genome contains coding strand DNA on 
both strands, rather than having a single continuous coding and non-coding strand (1). 
The six genes include Large Tumor antigen (LgT), Small Tumor antigen (SmT), major 
viral capsid protein 1 (VP1) and minor viral capsid proteins 2 and 3 (VP2 and VP3), as 
well as the BK Agnoprotein (Figure 5). The early genes are large and small T antigen. 
Large T, in particular, plays a major regulatory role and is required for viral replication 
and productive infection (14). One of Large T antigen’s major functions is to bind to and 
inactivate the tumor suppressor proteins Rb and p53, thereby removing a key block on 
the host cell’s entry into the cell cycle (42).  
Late gene products include VP1, VP2, VP3, and BK Agnoprotein. VP1 comprises 
the majority of the BKV capsid surface area; for every VP2 or VP3 capsid subunit 
present on the capsid surface, there are five VP1 subunits (14). VP2 and VP3 transcripts 
are generated from the differential post-transcriptional processing of a single mRNA 
transcript (14). The topology of the BK capsid is such that VP2/3 expression can only be 
detected after partial proteolytic degradation and viral uncoating in the endoplasmic 
reticulum (Figure 5; (25)). Thus, VP2/3 expression can be used as a marker of BKV ER 
localization (25). 
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Figure 5. Diagram showing topographic relationship between VP1 
(green) and VP2 (purple) BKV capsid proteins along a single axis. ‘C’ 
and ‘N’ denote carboxy- and amino-termini of the VP2 primary amino 
acid protein sequence. Note that if viewed in three dimensions, three other 
VP1 subunits would surround and encapsulate the VP2 subunit, thus 
effectively ‘sheltering’ the latter from the extracellular space. Figure 
modified from Kahlili and Stoner, 2001 (8).  
 
 Certain BK genes, such as Large T antigen, are transcribed and translated early in 
the BKV lifecycle, while others, such as VP1, appear later in the viral lifecycle. This 
distinction can be taken advantage of experimentally. Large T antigen can be interpreted 
as a marker solely of viral entry, rather than productive infection, whereas presence of 
VP1 DNA can be seen as a marker of productive (i.e. successful) infection, where BK 
capsid proteins are being constructed inside the host cell, in preparation for release into 
the extracellular environment.   
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The exact function of the final protein of the BK genome, BK Agnoprotein, 
remains contested. It is thought that BK Agnoprotein assists in BK virion assembly and 
release, by acting as a nuclear localization signal for VP1 during capsid formation, and as 
a viral ionic channel in host cell membranes (41, 43).  
The non-coding regulatory region (NCRR) contains the origin of replication as 
well as several transcription factor binding sites, and is often hyper-mutated (rearranged) 
in productively-infecting BK strains (14). Wild-type BK virus possesses a non-rearranged 
form of the NCRR; rearranged BK strains are often found in the epithelial cells of renal 
biopsies of patients with BKVAN (14). It has been hypothesized that rearrangements 
must occur in order for the virus to become capable of productive infection (20). 
Transcription and translation of all BKV genomic proteins are critically facilitated 
the expression of Large T antigen. Factors affecting the expression of Large T antigen 
will therefore secondarily affect levels of all BKV proteins, as well as the rate and 
efficiency of BK viral replication overall. Such factors include BKV’s ability to 
productively infect the host cell (and deliver its genome to the nucleus; discussed below); 
the degree to which BKV can establish latency and evade host immune surveillance 
mechanisms; and/or the availability of host cell replicative machinery (i.e. competition 
with host cell molecules for access to DNA polymerases or ribosomal components). This 
third factor is critical in the rationale for using an mTOR pathway inhibitor as an antiviral 
therapy.  
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Cellular Basis of BKV Attachment and Infection 
 
Many steps in BK viral infection, from attachment and virion trafficking, to 
nuclear entry and genome replication, are cell-type specific. A consensus has been 
reached, however, regarding certain intracellular events shared across cell types. BKV 
preferentially attaches to renal epithelial and urothelial cells, via ganglioside motifs 
present on its capsid, and the host cell ganglioside receptors GD1a and GT (Figure 6 
below, shows a proposed model of BKV infection; (23)).  
BKV internalization is accomplished by a caveolin-mediated endocytotic 
mechanism – one similar to, although independent of, clathrin-mediated uptake. Caveolae 
are detergent-resistant, cholesterol rich membrane invaginations that bud internally into 
the cytoplasm after BK viral binding to extracellular receptors. Caveolae are stabilized by 
caveolin-1 expression (24).  
Once internalized, BKV hijacks a number of host cell pathways and processes to 
facilitate its transport into the host cell nucleus (Figure 6). BKV-containing vesicles 
become acidified, causing partial viral decoating and breakdown of disulfide bonds, and 
migrate in a retrograde fashion along microtubules towards the trans-face of the Golgi 
apparatus (25). BK virions subsequently move towards the cis-face of the Golgi 
apparatus, and bud into vesicles that migrate to the rough ER (rER). Arrival to the rER 
has been postulated to be eight hours post viral infection, although the specifics of how 
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BKV controls the signaling and temporal nature of these retrograde trafficking events 
have yet to be elucidated (25, 26). Recent evidence indicates that BKV then enters the 
cytosol from the rER by hijacking the endoplasmic reticulum associated degradation 
(ERAD) pathway (27). The ERAD is a large group of ER-associated trans-ER-membrane 
proteins that recognize and remove misfolded or abnormal proteins as they arise over the 
course of modification in the ER (27). Proteins targeted by ERAD machinery are poly-
ubiquitinated as they are shunted into the cytosol, triggering their localization to 
proteasomes, where protein disassembly occurs (27). ERAD has also been implicated in 
the regulation of overall levels of certain proteins in the cell, such as HMG CoA 
reductase, the rate-limiting enzyme involved in cholesterol synthesis. During times of 
adequate or excessive cholesterol, ERAD machinery is selectively up-regulated to target 
HMG-CoA reductase (27). When seen in this light, the ERAD pathway could be seen as 
a form of post-translational regulation.  
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Figure 6. Model of the proposed major steps in BK viral infection of 
renal epithelial cells. Binding of BKV to ganglioside receptors on the 
host cell surface (A) triggers caveolin-mediated endocytosis (B). The BK-
containing endosome subsequently merges with an acidic endosome (not 
shown), which decreases pH and begins the viral uncoating process (C). 
Recent studies have shown that the virion-containing endosome then 
directly merges with the endoplasmic reticulum (E) and further viral 
uncoating occurs. BK virions hijack Endoplasmic Reticulum Associated 
Degradation (ERAD) transmembrane proteins (such as Derlin-1) present 
in the ER to facilitate their transport into the cytosol (F). The low-Ca2+ 
environment in the cytosol further facilitates viral uncoating and exposure 
of the BK genome (26). The genome is then transported via an unknown 
mechanism into the host cell nucleus. Figure modified from Jiang, et al., 
2009 (26).  
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BK Viral Reactivation 
 
Under certain circumstances, BK viral reactivation may occur, as previously 
latent BKV switches to a lytic phase inside the host cell. Once reactivation is triggered, 
the virus begins to replicate its genome and use host cell machinery to transcribe and 
translate viral proteins, in preparation for cell lysis and the release of viral progeny. This 
reactivation can occur in a variety of situations and tissues, and lead to several uniquely 
defined disease states (Figure 7). 
 
 
 
 
Figure 7. Common predisposing factors of BK viral reactivation, and 
potential pathologies associated with such reactivation. Importantly, 
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low levels of BK reactivation and viruria can persist without progression 
to viremia or disease. Iatrogenic causes of immunosuppression include 
immunosuppressive medications given during cancer treatment 
(chemotherapy, radiation therapy), as well as pre- and post-organ 
transplantation immunosuppression therapy. BKVAN: BK virus 
associated nephropathy.  
 
 Although the molecular triggers for reactivation are poorly understood, 
physiologic stress of host cells, moderate or severe immunosuppression, corticosteroid 
use, and physical trauma may all promote viral reactivation (28). In general, these 
triggers collectively activate pro-growth or cell cycle regulatory components which 
render the host cell permissive for viral replication (28). One such pro-growth 
intracellular signaling circuit, the “phosphatidylinositol-3-kinase/Akt1/mammalian target 
of Rapamycin” (PI3K/Akt/mTOR) pathway, has been shown to be activated by BKV, 
and is currently under study as a target for BKV antiviral treatments (22).  
 
BK Virus Associated Nephropathy 
 
BKV reactivation is a known risk factor for a common BK-induced disease, BK-
virus-associated nephropathy (BKVAN; (14)). BKVAN is the direct result of BK viral 
reactivation and replication in the renal urinary tract, and is similar histologically to 
nephropathy caused by other viruses such as CMV or JCV (29). BKVAN is defined as a 
persistent (>3 weeks) period of BK viruria, a plasma PCR viral load of greater than 
10,000 genomes/mL, as well as histological evidence of productive BKV infection in the 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1 Akt is also referred to as Protein Kinase B (PKB). 
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kidney (29). Renal biopsy of focal BK-positive lesions remains the diagnostic gold 
standard for this disease (29, 30).  
The majority of the structural and cellular damage to the kidney in BKVAN may 
be due to immune system invasion and destruction of the tissue, rather than directly due 
to the virus’ lytic reactivation (13). 1 – 10% of renal transplant recipients experience 
some degree of BKVAN, which has become recognized as a leading cause of graft failure 
(31). BKVAN diagnosis is made on average 44 weeks post kidney transplantation, with a 
mode of 24 weeks (32). The most common complication related to BKV reactivation is 
uretal stenosis in bone marrow transplant patients, which occurs (from all causes) in 10-
25% of bone marrow transplant recipients (1).  
 Overall immunosuppression is most severe in the acute post-transplant phase; thus 
it is during this period that renal transplant patients are most likely to develop BKVAN. 
Immunosuppressive burden is the single most important predictor of BKVAN prognosis 
(1). Other prognostic factors include measures of the BK serum viral load, severity of 
cytopathic cellular changes in infected renal tubule cells, and promptness of clinical 
diagnosis (1). The severity of BKVAN in the renal transplant setting, as well as other 
diseases associated with BK virus, warrant further research into strategies to reduce BK 
viral replication.    
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Difficulties in BKVAN Diagnosis 
 
The nature of BKVAN, however, makes a straightforward clinical diagnosis 
difficult. There are diagnostic and technological realities that often reduce the level of 
certainty with which the clinician can draw conclusions about the presence or absence of 
BKV-associated renal pathology (14). As an example, since BKVAN is a focal disease, a 
negative biopsy result does not necessarily rule out its presence (31). Thus, clinicians 
have had to resort to making predictions based on incomplete information, relying on 
trends in systemic levels of the virus over time.  
Detection of histopathological urinary decoy cells that contain BK virions may 
also represent a confounding variable for clinicians attempting to diagnose BKVAN (see 
Figure 2, page 6). Such decoy cells are shed during active replication and BKVAN, but 
are also shed asymptomatically during periods of normal health, by up to 54% of 
individuals (33, 34). Furthermore, histologically identical decoy cells are also produced 
during active JCV and adenovirus infections (35, 36).  
An additional difficulty facing clinicians is a wide differential diagnosis in 
patients who may have BKVAN. Potential pathologies producing a similar clinical 
picture include acute kidney rejection, GVHD, or other viral kidney infections that result 
in a similar presentation (13). Two major factors that predispose individuals towards the 
development of BKVAN are (1) the relative efficacy of BK viral replication, and (2) the 
failure of the host immune surveillance mechanisms designed to keep viral replication in 
check: i.e. BK-specific CD-8+ T cell responses. Assays currently developed in 
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immunology laboratories may in the future provide clinicians with tools to monitor the 
status of these markers of BK disease progression. These tools include viral challenge, 
immunophenotyping, and cytokine release assays, which characterize host 
immunological fitness and evaluate virus-specific immune responses (13). 
 
Monitoring BK Viral Load: the Quantitative Polymerase Chain Reaction Assay 
 
The BK ‘viral load’ is an estimation of the number of viral genomes present in a 
body compartment. The status of BK replication in at-risk patients can be inferred from 
the viral load in both the blood and urine, using quantitative PCR (qPCR) assays. qPCR 
is a common molecular biology technique used to simultaneously amplify and quantify 
the original number of copies of genetic material in a sample (37). This is accomplished 
by adding several components to samples containing ‘template DNA,’ which is the 
specific section of DNA (mammalian, viral, or otherwise) being artificially amplified in 
the laboratory. These components include: (1) Taq Polymerase, a heat-stable DNA 
polymerase originally isolated from the bacterial thermophile species Thermus aquaticus, 
(2) a Fluorescent ‘reporter’ dye attached to a probe, which is designed to dissociate from 
the probe/DNA polymerase complex when replication occurs, and reattach after the 
process has finished, (3) single nucleosides used to synthesize new DNA strands, and (4) 
ions and other molecules in a buffered solution (37). The sample is then placed in a PCR 
machine and heated at various temperatures to facilitate the creation of ‘amplification 
cycles’ (Figure 8). This assay is also known as ‘real-time’ PCR, because copy number is 
	  20 
assessed (florescence is measured) at the end of each and every amplification cycle, in 
‘real time.’  
 
 
 
 
Figure 8. Model of BKV DNA amplification process during the 
quantitative (‘real-time’) Fluorescent Polymerase Chain Reaction 
assay. Amplification cycles consist of repeated (x40), controlled heating 
of the sample to specific temperatures for specific lengths of time, in 
discrete denaturation (1), annealing (2), and elongation (3) steps. During 
the denaturation step (1), the sample is heated to 95°C. At this 
temperature, double-stranded DNA dissociates into single strands, which 
can then be accessed by the forward and reverse RNA primers (which 
facilitate polymerase binding), a Fluorescent RNA probe and Taq 
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Polymerase. Annealing (2) of the RNA primer upstream of the target of 
interest occurs next, in this case a specific region of the BK VP1 gene, at 
the optimal temperature of 60°C. A final elongation step (3) occurs 
simultaneously with annealing, at 60°C (this is not always the case, but 
happens to be for VP1 amplification specifically). During this step, Taq 
Polymerase molecules, which are present in excess in the sample, bind to 
and replicate all target DNA in the sample. 
 Repetition of these steps occurs sequentially for 40 cycles, and 
results in exponential amplification of the target sequence specifically. 
The RNA probe is responsible for producing the Fluorescent signal that is 
detected by the PCR machine during each amplification cycle. Most RNA 
probes used in qualitative PCR are designed to contain two Fluorescent 
dyes, a ‘quencher’ and a ‘reporter’’ (38). These two dyes remain in close 
proximity to one another on the probe, in a ‘quenched’ (non-Fluorescent) 
3D conformation. However, when the probe is bound to a section of DNA, 
and Taq polymerase moves past it, the conformation of the probe is 
changed in such a way as to release the ‘quencher’s’ inhibition of the 
reporter dye. No longer inhibited, the reporter dye then fluoresces at a 
specific wavelength which can be measured by a detector within the PCR 
machine. 
Importantly, the ‘quencher’ reattaches to the probe after each 
amplification cycle, resuming its inhibition of ‘reporter’ florescence (38). 
In this way, florescence is emitted during each cycle – although the PCR 
machine is not sensitive enough to measure florescence emitted during the 
earlier cycles (1-20), it is able to use florescence data from later cycles to 
extrapolate ‘backwards’ to determine the original quantity of target DNA 
in the sample. This ability makes qPCR an attractive tool for measuring 
viral loads (i.e unamplified DNA) in patient blood, urine, cerebrospinal 
fluid (CSF), or respiratory sputum. Image modified from:    
http://serc.carleton.edu/microbelife/research_methods/genomics/pcr.html.   
 
Add in 2 min incubation at 50C; this is to ‘clean the sample up’ by digesting 
any residual components that may be present; prior to actual amplification. Uracil 
instead of tymidine? UDG?  
Because of the risk of BK viral reactivation during organ transplantation, it is now 
standard procedure for renal transplant teams to monitor BK viral status in the blood and 
urine at regular intervals, both pre- and post-transplant, using qPCR. BKV generally 
	  22 
appears in the urine (viruria, which can be asymptomatic) before it can be appreciably 
measured in the bloodstream (viremia). One study showed that BK virions are shed 
periodically in the urine by up to 40% of immunocompetent adults, implying that 
immunosuppression is not required for viral reactivation (13, 39).  
 
Treatment of BKV-Induced Disease 
 
To date, there are no BKV-specific antiviral agents approved by the FDA for 
clinical use. Current treatment approaches for BKVAN and other BK-induced diseases 
center around early and consistent monitoring of BK viral load, both pre- and post-
transplant, and adjustment of the patient’s immunosuppressive regimen, if needed. 
Although some antiviral medications (e.g cidovir, leflunomide, quinolones, or 
intravenous immunoglobulin G) are commonly prescribed by physicians, their use has 
not been validated or standardized, and they have had limited clinical effectiveness (1). If 
BK-induced disease is suspected (i.e., if a decline in kidney function accompanied by a 
plasma BK viral load of ≥ 10,000 genomes/mL), a prompt reduction of the systemic 
immunosuppressive medications used to help prevent organ rejection is generally 
indicated (30).  
The rationale is that by lifting iatrogenic immune suppression, the host immune 
system will more efficiently eliminate BK-infected cells (22). As might be expected, this 
approach can easily result in harm to the patient, as a reduction of immunosuppression 
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increases the likelihood that recipient immune system cells will target and attack the 
donor organ.  
Despite the risk of organ rejection, the alternate consequence, that of unchecked 
BKVAN, is the more immediate concern when deciding how to manage 
immunosuppression in the face of presumed BK viral reactivation. BK-associated disease 
in the setting of kidney transplantation is a significant cause of kidney graft rejection 
(29). Further randomized clinical trials are needed to define the best strategy for 
immunosuppression reduction in the setting of polyomavirus-mediated disease. In 
addition, better antiviral agents are required, given the current poor outcome of grafts 
after development of BK nephropathy (40). The development of targeted anti-BK 
therapies stands to provide enormous benefit to transplant medicine. 
 
Overview of the PI3K/Akt/mTOR Pathway 
 
The pro-growth “phosphatidylinositol-3-kinase (PI3K)/Akt/mammalian target of 
Rapamycin” (mTOR) pathway is a key intracellular signaling pathway in host cells. The 
mTOR pathway is critically and centrally involved in regulation of multiple ubiquitous 
intracellular cycles, including cell proliferation, apoptosis, survival, metabolic activities, 
and regulation of protein translation (44, 45). There are several regulatory and feedback 
mechanisms in place to prevent excessive or reduced activity of this pathway (46, 47). 
External inputs to the mTOR system include nutrient availability, hypoxia, and growth 
factor binding the host cell surface (46).  
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Phosphoinositide-3-Kinase  
 
Phosphoinositide-3-Kinases (PI3K) are a diverse class of protein kinases that 
regulate many key cellular functions via phosphorylation (48). One class of PI3Ks, Class 
I, represents the most upstream regulatory component of the mTOR pathway. Class I 
PI3Ks are comprised of a p110 catalytic subunit, and a p85 regulatory subunit (49). Both 
of these subunits represent important substrates for targeted pharmacological inhibition 
(50). 
Class I PI3K phosphorylates a group of phospholipids known as 
phosphatidylinositols (PIs), so named for their inositol sugar head groups. PIs are a key 
component of all mammalian plasma membranes.  Class I PI3Ks uniquely phosphorylate 
Phosphatidylinositol (4,5) bis-phosphonate (PIP2), at the ‘3’ carbon position, thereby 
creating Phosphatidylinositol (3,4,5) tri-phosphonate (PIP3) (51).  PIP3 is a key regulator 
of several downstream intracellular pathways, which it mediates via its binding sites for 
plextrin homology (PH) domains. PH domains are common conserved binding motifs 
found in many signaling proteins, which act to localize the molecules that contain them to 
specific cell compartments or membranes (51). 
These motifs represent the molecular mechanism by which PI3K regulates 
multiple intracellular signaling pathways and circuits, including the mTOR pathway (50).  
Both PDK1 and Akt, contain PH domains (51). Once both molecules are brought into 
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close contact with each other via PIP3 binding, PDK1 phosphorylates Akt at an activation 
site, Threonine-308 (52). This results in downstream activation of the mTOR pathway.   
 
Akt: Protein Kinase B 
 
Akt (Protein Kinase B; PKB) is a class of serine/threonine kinases that play 
central roles in the regulation of multiple intracellular signaling pathways, including the 
activation state of the mTOR pathway. Akt causes mTOR activation indirectly, through 
the phosphorylation and inactivation of two molecules that constitutively inhibit mTOR 
complex 1 (mTORC1) activity, PRAS40 (proline-rich Akt substrate of 40 kiloDaltons’) 
and the tuberous sclerosis complex 2 (TSC2) (see Figure 12; (53)). Dysregulation of Akt 
signaling or expression has been shown to promote metastasis and oncologic disease 
progression, either through attenuation of this mechanism, or any of the myriad other 
functionalities of Akt (54).  
 
mTORC1 and mTORC2: central mediators of mTOR pathway activity 
 
The mTOR pathway’s major downstream effectors are two similar 
serine/threonine kinases, mTOR complex 1 (mTORC1) and mTOR complex 2 
(mTORC2). Both complexes contain mTOR itself (Figure 9). mTORC1 regulates protein 
synthesis globally, and couples cell size to cell cycle progression, while mTORC2 
regulates cytoskeletal dynamics (47). Down-regulation of mTOR expression equally 
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affects the functioning of both of these complexes. Importantly, mTORC1 is susceptible 
to inhibition by Rapamycin, while mTORC2 is resistant to such inhibition. mTORC1 
activation controls the downstream regulators of protein translation 4E-BP and P70S6K 
(47). mTORC2 is not involved in regulating these proteins; instead mTORC2’s major 
function is thought to be activation of Akt via phosphorylation at Serine-473 (52).    
 
 
 
Figure 9. Schematic compositions of mTOR complexes 1 and 2. 
mTOR is a key component of both complexes. mTORC1 uniquely 
contains Raptor and Pras40, and mTORC2, comprised of Rictor, Protor, 
and Sin1. Note that Rapamycin, while conjugated to FKRP-12, selectively 
inhibits the activity of mTORC1 and not mTORC2. Image taken from 
Bhaskar and Hay, 2007 (47).  
 
Dysregulation of the PI3K/Akt/mTOR Pathway 
 
Overexpression of the components of the mTOR pathway, particularly PI3K, have 
also been shown to be involved in the pathogenesis of multiple diseases. These include 
diabetes, cardiac hypertrophy, degenerative diseases, and cellular senescence (44, 45, 55).  
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PI3K is one of the most commonly mutated oncogenes in all of cancer biology, 
and its dysregulation has been implicated in the progression of a wide range of cancers, 
including breast, colon, endometrial, hepatocellular, and certain lymphatic and leukemic 
neoplasias (45, 53). The most direct causes of aberrant PI3K signaling are 1) loss of the 
tumor suppressor gene PTEN, which is a major inhibitor of PI3K activity, 2) activating 
mutations of either the α or β isoforms of the p110 catalytic subunit, or 3) activating 
mutations in any one of many growth factor receptors that regulate PI3K activity (50). 
Furthermore, many types of cancer are caused by the loss of tumor suppressor proteins, 
such as p53 or APC, which constitutively inhibit mTOR components, and thus indirectly 
cause an increase in their expression levels (55). Not surprisingly, the search for specific 
and potent inhibitors of members of the PI3K/Akt/mTOR pathway has been the focus of 
considerable interest by researchers in recent years (56).  
 
mTOR Pathway Inhibition 
Inhibition of the mTOR pathway at multiple levels has important consequences. 
One well-known problem in rational mTOR inhibitor design is that inhibition of 
mTORC1 alone causes a feedback activation of PI3K/Akt upstream signaling (57). The 
feedback activation of PI3K and Akt, resulting from selective mTORC1 inhibition, may 
counter the potential therapeutic benefits of such inhibition (57). This may explain the 
only modest effectiveness of rapamycin in treating human disease (sirolimus, and its 
derivative everolimus, for which the mTOR pathway was originally named), and explain 
its cytostatic rather than cytotoxic effects in some animal models (57, 58).   
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Similarly, feedback activation has been noted during the targeted inhibition of 
PI3K, using the PI3K-selective inhibitors wortmannin (irreversible) and LY294002 
(reversible) (59). Such positive feedback activation may be the result of decreased 
expression of PS6K, which is engaged in constitutive negative feedback of PI3K. Perhaps 
as a result of this mechanism, both of these compounds have shown serious cytotoxicity 
in animal cellular models, and have consequently not been advanced to human clinical 
trials (59).   
The extent of such feedback loop involvement may vary widely across the 
spectrum of cancers and virologic infections induced by PI3K dysregulation, and 
researchers must be careful about just how they go about inhibiting and manipulating this 
pathway. mTOR dysregulation (inhibition as well as stimulation) may up-regulate other 
potentially oncogenic cell signaling pathways, and thus affect levels of intracellular 
signaling molecules in unpredictable ways. For example, selective mTORC1 inhibition 
has been shown to activate the MAPK pathway, which has long been known to promote 
uncontrolled cell growth (60).  
 Further research into the biochemical and cell-signaling basis for how aberrant 
cell growth is induced, in an infectious or neoplastic setting, may help clinicians make 
point-of-care decisions about which combinations of PI3K/mTOR inhibitors (i.e pan-
PI3K, isoform-specific PI3K, dual mTOR/PI3K, or mTOR-specific) to give to patients 
(61). Ultimately, more well-informed treatment decisions will lead to better disease 
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management and control, and a better quality of life for patients who are afflicted by 
diseases or viruses involving mTOR pathway dysregulation. 
 
BK Viral Upregulation of the mTOR Pathway 
 
Recent studies have shown that during active infection, BKV upregulates the 
expression of multiple components of the PI3K/Akt/mTOR pathway (Figure 10; (22)):  
 
 
 
Figure 10. Sites of BKV activation and targeted pharmacological 
inhibition of the mTOR pathway. Green arrows indicate direct BKV 
upregulation: phosphoinositide-dependant protein kinase 1 (PDK1), Akt 
(PKB), mTOR, and the downstream mTOR effectors 4EBP-1 and 
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p70S6K. Note that mTORC2 interactions are not shown. Sites of targeted 
pharmacological inihbition of the mTOR pathway are also shown; 
dactolisib (BEZ-235) is in purple, leflunomide and sirolimus are in red. 
The latter two drugs are commonly used immunosuppresive medications 
given to renal transplant recipients. Leflunomide is a targeted inhibitor of 
Akt and PDK-1, and possesses both antiviral and immunosuppresive 
activity (62). Sirolimus, the commercial name of rapamycin, for which the 
mTOR pathway is named, directly inhibits mTOR complex 1 (mTORC1). 
Ovals or perpendicular lines indicate inhibition, arrowheads indicate 
activation. Modified from Liacini, et al., 2010 (22).  
 
BK-induced stimulation of the mTOR pathway causes, among many other effects, 
(1) increased phosphorylation (and activation) of the downstream mTOR effector p70S6 
kinase (P70S6K; whose major role is as an upstream regulator of global levels of protein 
translation in the host cell), as well as (2) increased phosphorylation of the binding factor 
4E-BP (22). Hypophosphorylated 4E-BP constitutively binds to and inhibits the protein 
eIF4E (elongation Initiation Factor 4E; Figure 11, (30)). mTOR activation induces 
FRAP-mediated phosphorylation of 4E-BP, promoting its dissociation from eIF4E, and 
binding of the latter to the 5’ cap of cytosolic mRNA (Figure 11). This eIF4E binding 
step must occur in order for the mRNA to be recognized by ribosomes and for translation 
to proceed (Figure 11; (63)).  
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Figure 11. Regulation of eIF4E binding to 5’ cap of mRNA 
transcripts. eIF4E availability is dictated by the phosphorylation 
status of the eIF4E binding protein, 4E-BP. Hyperphosphorylation of 
4E-BP by the FRAP kinase (FKBP-12-rapamycin associated 
protein)/mTOR complex causes 4E-BP dissociation from eIF4E. Unbound 
eIF4E is then free to bind to the 5’ cap of mRNA transcripts along with 
eIF4G, promoting protein translation initiation. Pharmacological inhibition 
of the mTOR pathway using agents such as rapamycin, would be expected 
to result in 4E-BP hypophosphorylation and reduced levels of free eIF4E. 
This would result in slower rates of translation initiation by decreased 5’ 
mRNA cap modification. Figure modified from Richter, et al., 2005 (63). 
 
Collectively, these two mechanisms increase the rate of translation of many kinds 
of proteins in the host cell, including ribosomes themselves (ribosomal biogenesis). 
Theoretically, any increase in the number of ribosomes by mTOR stimulation allows 
BKV to replicate its genome in an increasingly efficient manner (22). In sum, the targeted 
activation of the PI3K/Akt/mTOR pathway by BKV represents an opportunity for mTOR 
pathway inhibitors to specifically reduce the rate of host cell protein translation, and 
thereby reduce viral replicative efficiency. 
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Choice of Targeted mTOR Pathway Inhibitor  
 
In the face of the limited clinical success of naturally occurring mTOR inhibitors 
such as rapamycin (which was originally isolated from Streptomyces hygroscopicus in 
1975, from a bacterium native to Rapa Nui, a.k.a. Easter Island), researchers have looked 
to rationally synthesized compounds for more effective PI3K pathway inhibition (64). 
The results are promising. To date, over 25 mTOR-selective, PI3K-selective, or dual-
inhibitor compounds have been identified and synthesized commercially by 
pharmaceutical companies such as Novartis, Pfizer, Astrazeneca, Merck, and others, and 
are in the process of intensive in vitro testing in several cellular models (45, 50).  
One such second-generation mTOR inhibitor is Dactolisib, trade name NVP BEZ-
235, which is a dual PI3K/mTOR inhibitor manufactured by Novartis Pharmaceuticals. 
BEZ-235 can be taken orally as a pill, once a day (65). This drug has been shown to 
strongly and specifically inhibit several components of the PI3K/Akt/mTOR pathway, 
including mTOR, PI3K, and the DNA-dependent Protein Kinases (DNA-PK) (Figure 12; 
(44, 61)).  
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Figure 12. Overview of signaling intermediates involved in the (A) 
mTOR pathway and (B) DNA damage response pathway, including 
sites of pharmacological inhibition. Akt upregulates mTORC1 
expression by phosphorylating and down-regulating the effectors PRAS40 
(proline-rich Akt substrate of 40kDa) and tuberous sclerosis complex 2, 
both of which are constitutive inhibitors of mTORC1 activity (59).    
 BEZ-235 (dactolisib; red) causes direct inhibition of 
Phosphotidyl-Inositol-3-Kinase (PI3K) as well as mTOR complexes 1 and 
2, as well as certain kinases involved in the DNA damage response: ATM 
and DNA-dependent protein kinases (DNA-PKs). Activation of the latter 
two targets by double-stranded DNA breaks induces cell cycle arrest and 
the DNA damage response.  BKM120 (dark blue) is an ATP-competitive 
inhibitor of PI3K; KU63794 (light blue) is an ATP-competitive inhibitor 
of mTOR itself, thus it effectively inhibits both mTORC1 and mTORC2, 
of which mTOR is a part. KU57788 (brown) and KU55933 (purple) 
selectively inhibit DNA-PK and ATM, respectively, via an ATP-
competitive mechanism. Figure modified from Shortt, et al., 2013 (45).  
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NVP BEZ-235 was originally designed as a potential targeted treatment for 
certain cancers caused primarily by PI3K-activating mutations, and is currently in Phase 
II clinical trials for certain indicated cancers (44, 65). Structurally, BEZ-235 is an 
aromatic nitroheterocyclic organic compound, with several benzene rings. This drug also 
contains an imidazole ring (Figure 13; (66)). Other drugs in the imidazole class of 
medications are used as antibiotics, to treat a wide variety of infections. These include the 
common hospital acquired bacterium Clostridium difficile (Metronidazole), as well as 
certain fungal, protozoan and anaerobic bacterial infections (67).  
 
 
Figure 13. Structural formula of the imidazole Dactolisib, trade name 
NVP-BEZ235. BEZ-235 has a molecular formula of C30H25N5O, molar 
mass of 469.5g/mol, and is a dual-PI3K/mTOR inhibitor currently being 
tested in clinical trials for some advanced-stage cancers. It is being tested 
as a potential antiviral agent in this thesis project. Imidazole ring is 
marked in red brackets. Figure modified from (66).     
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The decision to use NVP BEZ-235 (Dactolisib) over other targeted mTOR 
pathway inhibitors reflects its unique characteristics, as well as its relatively broader 
inhibition of multiple mTOR pathway targets. These traits set BEZ-235 apart from other 
mTOR inhibitors, particularly mTOR-selective inhibitors such as everolimus or 
sirolimus, and make it an ideal candidate molecule for novel testing as an antiviral agent.   
 
Current Experimental Approaches to Studying BKV  
 
There is no animal reservoir for BKV; the virus is capable of establishing latent 
infection in only certain human cell types (renal epithelial cells, among others). As such, 
there is no animal model currently available for BKV study. This fact severely limits the 
scope and nature of the experiments that BKV researchers can carry out. Without access 
to an animal model, it is difficult to characterize, manipulate, and study immune 
responses to BKV infection. The ability to infect rats or mice, for example, with BKV 
would allow researchers to fully explore the interplay and dynamics of different immune 
system cells as they respond to a BKV infection (i.e. antigen-presenting cells and BKV-
specific CD8+ T-cells). Currently, many clinical studies are retrospective or observational 
in nature. 
The ongoing research in the Tan laboratory involves analysis of kidney transplant 
patients’ cellular adaptive immune responses against BKV over time (temporal changes 
in the proportion of the CD8+ BKV-specific T cell population, both before and after the 
implantation of the transplanted organ). Patient blood and urine samples are received at 
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regular intervals, and PBMCs are isolated and challenged with BKV. Tetramers of MHC-
I molecules that artificially express BK-VP1 peptide are incubated with patient PBMCs, 
and then either analyzed via flow cytometry or intracellular staining techniques. The 
results of these experiments are then correlated with clinical outcome (development of 
BK viruria, viremia, or BKVAN), in an attempt to understand more about interactions 
between BKV and the host immune system.  
 BKV research at Beth Israel Deaconness Medical Center centers around the use 
of cellular models of BKV infection, incorporating ‘immortalized’ renal proximal tubule 
epithelial (RPTE) cell lines, particularly CCD-1105. Other studies have used the 
fibroblast cell line CV-1 for BK in vitro studies (23). Cell lines are said to be 
‘immortalized’ if they are theoretically able to replicate indefinitely, when given proper 
growth conditions. The immortality of cellular cultures is often accomplished via 
genomic insertion of the SV40 Large T antigen or other oncogenic viral proteins (68).  
This artificial genetic manipulation is relevant when staining for BK Large T 
antigen produced in virally infected host cells – particularly those cell lines immortalized 
with SV40 Large T antigen. Because no commercially-available monoclonal antibody for 
BK Large T exists, researchers instead use the cross-reactive polyclonal SV40 Large T 
antigen to stain for this BK protein, from Santa Cruz Biotechnology, CA. As might be 
expected, this polyclonal antibody may bind to SV40 Large T antigen produced at low 
levels endogenously in these cell lines. Results of assays involving BK virally infected 
cell lines that have been immortalized with SV40 Large T antigen must be interpreted 
carefully in order to minimize over-estimation of Large T expression. In order to prevent 
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this very problem, the cell line used in this project, CCD-1105 renal epithelial cells, were 
immortalized using oncogenic human papillomavirus 16 proteins [CCD 1105 KIDTr 
(ATCC CRL-2305TM), ATCC, Mannassas, VA).  No cross-reactivity with SV40 Large T 
antigen antibodies occurs in this cell type.    
Some studies suggest that renal tubule cell populations taken directly from animal 
or human tissues (‘primary cell lines’), rather those that have been artificially 
immortalized, provide more realistic intracellular environments for the study of BKV 
infection and replication (69). However, such cultures are more time-consuming to 
maintain, and ultimately do not provide the standardization, consistency, and 
reproducibility of immortalized cell cultures.  
 
Aims of the Proposed Study  
 
This thesis project is an attempt to evaluate the efficacy of the dual-PI3K/mTOR 
inhibitor NVP BEZ-235 (Dactolisib) as an antiviral agent, in a cellular model of BKV 
renal infection. It will attempt to show conclusively that BEZ-235 indirectly reduces the 
replicative efficiency of BK virus, via down-regulation of components of the mTOR 
pathway.  
A drug toxicity screen was carried across a range of experimental BEZ-235 
concentrations (0nM – 1000nM), using the MTT assay. Culture and preparation of cells 
for this assay followed an identical time-course and procedure to that of the subsequent 
experimental trials, to determine if the drug induced any significant degree of 
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cytotoxicity. Following positive findings from this screening (a lack of significant 
observed cytotoxicity), further experimentation was carried out.  
Cells were grown according to established and standardized protocols, under 
sterile conditions. After plating, each well was ‘pre-incubated’ for 48 hours with 
appropriate concentrations of BEZ-235, and then infected with BK virus (or 
independently with SV40 virus, if indicated). Virus was then removed from the 
supernatant, and cells were allowed to grow in fresh media for a further 48 hours. One of 
three types of assays were then carried out to investigate the extent of viral replication: 1) 
quantitative PCR measuring number of viral genomes found intracellularly in each 
sample, 2) Western blot analysis for levels of proteins in the mTOR pathway or viral  
proteins, or 3) immunohistochemical staining for the number of Large-T-antigen 
expressing cells.  
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METHODS 
 
Drug Toxicity Screening – the MTT Assay 
 
As Paracelsus famously said in the early 1500s, ‘the dose makes the poison;’ this 
toxicological concept still rings true today (70). Any compound, even water, which most 
see as essential for life, can be toxic to the human body, given a dose of sufficient 
strength.  
In order to begin testing the research question, it was first necessary to confirm 
that BEZ-235 was, in fact, not toxic to the cells themselves at the concentrations used. 
Drug-induced cell toxicity of any type represents a confounding factor that must be 
screened for prior to the start of any viral infection studies. This is especially true because 
the degree of BEZ-235 cytotoxicity is concentration-dependent, and all assays will be 
carried out on a wide range of drug concentrations.  
Poisoned cell populations are likely to have overall dysregulation of metabolic 
activity, higher levels of stress-induced cytokines, and accumulation of lysed cellular 
debris in the extracellular space. Importantly, many of the major intracellular pathways 
will likely also be abnormally expressed, including the mTOR pathway, which is the 
major focus of this project. For all these reasons, drug-induced cellular toxicity may 
adversely affect cellular responses to BK infection, and potentially invalidate any and all 
results we might obtain from experimental assays.  
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There are several well-validated cell cytotoxicity assays that are commercially 
available. Most of these assays allow for quantitative determination of the ratio of live to 
dead cells in any given cell population. The Vybrant MTT Cell Proliferation assay 
(Molecular Probes - Life Technologies, Grand Island, NY), which is a rapid, easily 
performed colorimetric assay that measures metabolism of the salt dimethyl thiazolyl 
diphenyl tetrazolium (MTT) was used in this study (71).   
Non-reduced MTT is a yellow compound, whose relative abundance in a cell can 
be approximated by spectrophotometer readings at 630nm. This compound is reduced 
enzymatically by mitochondrial succinate dehydrogenase (familiar to biologists as 
Complex II of the electron transport chain), into an insoluble purple product. The rate and 
overall relative abundance of the reduced and oxidized forms of MTT is dependent on the 
overall metabolic status of the cell (72). Dead cells will contain only non-reduced 
(yellow) MTT, and will thus not contribute to the intensity of purple color produced in a 
given well. Colorimetric purple intensity can be determined using a spectrophotometer 
measuring light produced at 570nm, and subtracting from that value any background 
signal, measured at 630 nm. Comparisons can then be made with this quantitative 
information, across conditions.  
 
Time-course of Culture of BEZ-235 Incubation and Viral Infection Protocol  
 
 Following positive preliminary results from the MTT assay using appropriate 
concentrations of BEZ-235, it was next necessary to determine an appropriate time-
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course of events during drug incubation and BK viral infection. This time-course was 
optimized and standardized at the beginning of the experimental period, and used as 
consistently as possible for all assays (Figure 14). 
  
 
 
 
Figure 14. Schematic of time-course of CCD-1105 drug pre-treatment 
and viral infection protocol for all experimental assays in this project. 
Note that glass chamber slides, rather than 6 well plates, were used for 
immunohistochemistry experiments. All other conditions were held 
constant.   
1mL aliquots of CCD-1105 cells (containing 1*106 cells) were 
individually thawed in a water bath and plated with ~14 mL of K-10 
growth media in a 175cm2 flask. After 48 hours of growth, cells were 
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plated in 6 well plates at 50K cells/well (exact cell counts were determined 
using a haemocytometer), and allowed to grow for a further 48 hours, with 
incubation of 3 mL of K-10 media containing appropriate BEZ-235 
dilutions. Cells were then washed with PBS and infected with BKV 
(stored at -80 oC) at MOI of 1.0 for 3 hours. Wells were then washed with 
PBS and replaced with 3 mL of K-10 media. Cell growth was observed via 
light microscopy at all stages of the time-course. 175 cm2 flask image 
taken from: http://www.sigmaaldrich.com/content/dam/sigma- 
aldrich/product5/020/cls3815.tif/_jcr_content/renditions/large.jpg  
 
  Standardization of CCD-1105 Population Life Cycles   
 
 Immortalized renal epithelial cells (CCD-1105 KIDTr, American Type Culture 
Collection (ATCC, CRL2305), Manassas, VA]) were purchased, and arrived in the 
laboratory at 133 days of growth. They were then grown in sterile tissue culture 
conditions in 175 cm2 flasks, using K-12 media (comprised of D-MEM R-10 base media 
(Gibco/Life Technologies, Grand Island, NY), 10% fetal bovine serum (Hyclone/Thermo 
Scientific, Waltham, MA), 1% gentamycin (Gibco/Life Technologies, Grand Island, 
NY), and 5% penicillin/streptomycin. ~80% plate coverage (confluency) was achieved 
after ~48 hours. At that time, cells were then ‘passaged’ into a new sterile flask at a ratio 
of 1:3.  
Prior to transfer, cells were washed once with Dulbecco’s Phosphate Buffered 
Saline (dPBS; Life Technologies, Grand Island, NY), rendered non-adherent with 2.5 mL 
of trypsin (TryoLE Select, Gibco/Life Technologies, Grand Island, NY) and 
homogenized in ~12 mL of media. 4 mL (representing a one third of the total cell 
population) of this suspension was then transferred to a new sterile 175 cm2 flask, and the 
cell population was allowed to settle and adhere to the flask surface. Thus, only one third 
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of the cell population was transferred to the new flask, so optimal cell growth could 
continue.The process was repeated until passage 8, when cells were frozen in 1mL 
aliquots of 1*106 cells at -130 oC, for use in all subsequent BKV/BEZ-235 assays.  
 
 Cell Plating, Growth, and BEZ-235 Incubation  
 
1mL aliquots of CCD-1105 cells were thawed as needed, and grown in 175 cm2 
flasks for ~48 hours. They were then plated in 6-well plates at 50,000 cells per well (see 
Figure14).  BEZ-235 drug treatments included 1000nM, 100nM, 10nM, and 0nM, as well 
as wells for MOI (‘Multiplicity of Infection’) determination and an SV40 positive control 
when appropriate (IHC assays only; explained below).  
After 48 hours of growth, media was aspirated (via vacuum aspiration), cells were 
washed once with PBS, and BEZ-235 was added at appropriate concentrations in 4 mL of 
media in 6-well plates (Figure 15).  
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Figure 15. Diagram showing the drug incubation conditions for cell 
populations contained in a six-well plate. The well for MOI 
determination was located in a separate plate, to minimize unnecessary 
handling and prevent contamination of the remaining wells.   
 
 Multiplicity of Infection (MOI) Determination  
 
Following 48 hours of BEZ-235 incubation, a cell count used to determine MOI 
was performed, and BK viral infection was carried out at an MOI of 1.0 for three hours. 
MOI is a quantitative ratio set by the researcher (usually 1.0, .1, .01, etc) used to 
standardize the number of infectious agents (bacterial, viral, or otherwise) added to a 
population of host cells, across experiments or research groups. This is important because 
cell populations grow at slightly different rates, even when all other conditions are held 
constant (number of cells plated, incubator humidity and CO2%, volume of cell culture 
media, etc). As a result, adding a constant number of virions to every experimental trial 
may not produce the same number of infectious events. On a cellular level, some CCD-
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1105 cells may be challenged by three or more BK virions, some by none at all. By 
determining the approximate number of host cells present in the well immediately prior 
to viral infection, and adding an identical number of virions (for MOI of 1.0), researchers 
can most accurately standardize the viral infection process, and thus reduce error.   
Cell counting was performed by trypsinizying and subsequently resuspending 
cells from a single well, in 1mL of media. 10 uL of cellular suspension was mixed via 
pipette with 90 uL of Trypan Blue, a cellular visualization agent (Gibco/Life 
Technologies, Grand Island, NY), creating a 1:10 dilution. 10uL of this dilution was then 
pipetted into plastic hemocytometers (Hycor Biomedical, Indianapolis, IN), which 
contain small grids comprised of 1mm by 1mm squares into which cellular suspensions 
can be injected. Live cells were systematically counted at 100x magnification, and 
independent counts in four of these squares were averaged and used to estimate the total 
number of cells contained within a 1 mL suspension. Specifically, this estimation was 
calculated using the following equation:  
 
 
 
Here, ‘X’ is the total volume of cellular resuspension, generally 1 or 2 mL.  ‘10’ 
represents the 1:10 Trypan Blue dilution, and ‘10,000’ accounts for conversion factors 
used in representing the volume of 1:10 dilution contained within a single ‘square’ of the 
hemocytometer.   
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Endpoint Assays for Measuring Efficiency of Viral Replication  
 
Upon the completion of 48 hours of further growth post-viral infection, all 
samples were centrifuged in 1.7mL microcentrifuge tubes, pelleted  (via aspiration of the 
supernatant), and frozen at -20º C. Samples were then thawed at room temperature 
immediately prior to analysis by one of three approaches: extraction of DNA followed by 
quantitative (real-time) Polymerase Chain Reaction (qPCR), analysis of protein content 
by Western blot, or Fluorescent protein staining with immunohistochemical techniques.   
 
  Fluorescent Real-Time Polymerase Chain Reaction 
 
 PCR is an attempt to quantify the exact amounts genetic material (from virus 
genomes as well as host cell genomes) present in each sample. Because genetic material 
is potentially present ubiquitously on all surfaces in the lab environment, it is imperative 
that strict cleaning protocols are followed. Lab coats, lab benches, reagents and pipette 
tips were stored separately and specified as ‘DNA extraction only’ or ‘PCR only.’ These 
materials were not used for other assays or by other laboratory workers. Prior to 
extracting DNA from frozen whole cell samples, all pipettes, tube racks, and any other 
supplies used in the biosafety cabinet were sprayed (with subsequent drying after each 
step) with 70% ethanol, then DNAZap (Ambion/Life Technologies, Grand Island, NY), 
then twice more with 70% ethanol.  
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 DNA extraction from experimental samples was carried out as per instructions 
contained within the Qiagen DNA Blood Mini Kit (Qiagen, Valencia, CA). Briefly, 
samples were lysed and run through a series of centrifugations with different lysis and 
wash buffers, as well as 95% ethanol, which efficiently precipitates the DNA. After the 
precipitated DNA had been washed sufficiently, 200 uL of a final buffer (Buffer AE) was 
added to dissolve the DNA and allow it to be collected in a microcentrifuge tube. The 
tubes were then frozen at -20 °C while PCR reagents were being prepared.   
 All PCR reactions were carried out in 96-well plates optimized for use in a PCR 
machine (MicroAmp, Applied Biosystems, Bedford, MA), with each sample and standard 
curve well (discussed below) being run in triplicate. 20 uL of each sample were added to 
30 uL of ‘Master Mix,’ (TaqMan Universal Master Mix, Applied Biosystems/Life 
Technologies, Grand Island, NY), for a total reaction volume of 50 uL. 
The Master Mix contained everything needed to carry out 40 consecutive cycles 
of Fluorescently quantifiable DNA amplification: 80 uL each of (1:20) BK VP1-specific 
forward (5'-AGTGGATGGGCAGCCTATGTA-3') and reverse (5'-
TCATATCTGGGTCCCCTGGA-3') primers (Invitrogen). Five uL of Fluorescent probe 
(6FAM-AGGTAGAAGAGGTTAGGGTGTTTGATGGCACA), also specific for the 
same VP1 sequence, containing both ‘reporter’ and ‘quencher’ dyes, Taq Polymerase 
(whose exact volume depended on the number of sample wells being run), an excess of 
nucleosides with which to create the newly synthesized DNA, and 335 uL of double 
distilled water. This mixture was pulse-vortexed and pipetted into the 96-well plate, and 
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then covered with a clear plastic sheet to prevent contamination. The plate was then 
refrigerated at 4 °C while standard curve dilutions were prepared. 
The ‘standard curve’ is a line-of-best fit that must be calculated anew with each 
and every PCR amplification of an experimental sample. This curve is generated using a 
serial dilution of a known number of genetic components: 106, 105, 104, 103, 102, 101, 5, 
and 0 copies. Care was taken to reduce any potential cross-contamination of genetic 
material between these dilutions as they were being made. The appropriate volumes of 
ddH20 were prepared prior to any plasmid being added to the dilutions. Microcentrifuge 
tubes containing any concentration of plasmid were opened with one arm underneath the 
lab bench, and closed in a similar position, to reduce aerosol contamination. The genetic 
material used to generate the standard curve in these PCR assays was a plasmid, pBR322, 
containing a full-length insertion of BKV (provided by the Koralnik Lab). The standard 
curve is needed for the PCR program (7300 System Sequence Detection Software [SDS], 
v. 1.2.3, Applied Biosystems) to accurately ‘back-calculate’ and interpret florescence 
data measured sample amplification in the thermocycler.  
Once prepared, serial pBR322 plasmid dilutions were briefly vortexed to 
homogenize the solution, and 20 uL was loaded onto the 96-well plate in triplicate. 
Experimental wells remained covered during the dilution plating process. A new plastic 
cover sheet was added and the entire plate was centrifuged at 2000 rpm for 2 minutes, to 
remove any droplets on the sides of wells. Samples were then placed in the 7300 Real-
Time PCR (Applied Biosystems), and run through 40 amplification cycles (described in 
the text of Figure 5).   
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Western Blot Protein Assays 
 
 Samples were thawed to room temperature and lysed in 200uL of lysis buffer 
(Cell Signaling, Danvers, MA), containing a 1:100 dilution of protease/phosphatase 
inhibitor cocktail (Cell Signaling, Danvers, MA) on ice for 15 minutes. 
Protease/phosphatase inhibition was needed because activated mTOR pathway proteins 
are phosphorylated at specific residues, and the state-dependent nature of this pathway is 
likely intensely dysregulated during the cells’ stressful period of cell lysis. Specifically, 
lysis of all host cell membranes will cause all cellular compartments (lysosomal, nuclear, 
endosomal, Golgi Apparatus, etc) and their contents to merge, including any proteases or 
phosphatases contained within each compartment.  
After incubation on ice, samples were then centrifuged at 8,500 rpm for 10 
minutes in the cold room. 12uL of sample was then combined with 12uL of loading 
buffer. Loading buffer was prepared by mixing Laemmli buffer (BioRad Laboratories) 
with 5% β-mercaptoethanol (BME; Sigma-Aldrich, St Louis, MO). BME is used in 
Western blotting applications to denature protein quaternary structure and prevent 
polymerization, which may affect gel migration rate and subsequent band formation. This 
mixture was then denatured in a heated water bath for 10 minutes. Samples were then 
allowed to cool to room temperature, and centrifuged briefly to remove droplets from lid. 
10% polyacrylamide pre-cast gels (Mini-PROTEAN TGX, BioRad, Hercules, 
CA) were immersed in running buffer (1:10 dilution of 10x Tris-Glycine SDS buffer 
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(BioRad) and placed in the gel apparatus (BioRad) prior to sample loading. A protein 
standard was also included in all gel runs (Precision Plus Protein Kaleidoscope Standard, 
BioRad) to allow for band size identification.  
Electric current was run across samples at constant voltage (100V; ~40mA) using 
a power source, for approximately 60-75 minutes, or until samples had run the length of 
the gel. Protein content was transferred from gel to membrane using an automated system 
(iBlot Transfer System, Invitrogen, Carlsbad, CA).  
The membrane was cut to size, washed for ten minutes twice in 0.05% Tween 
Tris-Buffered Saline (TBS-T) solution (BioRad), and blocked in a 5% bovine serum 
albumin-TBS solution for one hour at room temperature, on a rocker. Both Tween and 
bovine serum albumin (BSA) are included in these washes as blocking agents; to reduce 
the non-specific binding of antibodies to proteins other than the target sequence. The 
membranes were then washed three more times (ten minutes each) with TBS-T, and 
incubated with rocking overnight in a 1:1000 dilution of ‘primary’ antibody in 3% BSA-
TBS solution at 4° C. The ‘primary’ antibody, is by convention specific for the target of 
interest, but is otherwise unable to be visualized. The addition of a ‘secondary’ antibody 
is required to detect the protein of interest.   
Primary antibody was then poured off, and the membranes were washed twice 
with TBS-T, and once with TBS, on a rocker at room temperature. A solution of 3% BSA 
in TBS-T, with ‘secondary’ antibody (at 1:1000 concentration), was then prepared and 
incubated with the appropriate membranes for one hour at room temperature, on a rocker.  
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The ‘secondary’ antibodies used in this study were conjugated with a specific 
enzyme, horseradish peroxidase, which cleaves its specific substrate to produce 
detectable levels of a luminescent signal. By convention, secondary antibodies are 
produced by the immune system of an animal or host distinct from that which produced 
the primary antibody that was used in the experiment. All mTOR pathway–specific 
antibodies used in this project were rabbit immunoglobulins, meaning they were 
produced and harvested from rabbits (Cell Signaling Technologies, Danvers, MA). Thus, 
for these proteins specifically, we used HRP-conjugated mouse anti-rabbit monoclonal 
antibodies as ‘secondary’ antibodies. Doing so allows us to most effectively visualize any 
primary antibody used to target proteins, and produce the most accurate signal pattern 
during development.  
After secondary antibody incubation, membranes were washed three times with 
TBS-T, and twice with TBS, for ten minutes each on a rocker. Immediately following 
this final wash, they were incubated for 5 minutes in ECL developer solution (Pierce 
Products, Thermo Fischer Scientific), and film negatives were produced in a dark room. 
Multiple exposures were produced to obtain the optimal image quality.   
 
Immunohistochemistry (IHC) Staining  
 
 Because imaging of fluorescently stained adherent cells is accomplished directly 
in the container in which the cells are grown, glass chamber slides (Nunc™ Lab-Tek™ II 
Chamber Slide™ System, Thermo Scientific), rather than 6 well plates, were used in the 
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IHC protocol. The smaller volume in these chambers also necessitated other small 
changes from the ‘standard’ experimental protocol: 500 uL of media were used during 
viral infections, and 1 mL of media was used per well, for all growth incubations.  
 Upon completion of the 48-hour post viral infection growth period, glass chamber 
slides were washed twice with 1 mL of PBS. Cells were then fixed via incubation with a 
4% formaldehyde solution (Polysciences, Incorporated, Warrington, PA), for 20 minutes 
at 4° C. The samples were brought from the tissue culture room to the wet lab, where 
chamber ‘walls’ were removed (leaving only glass microscopy slides). Slides were 
permeabilized with .2% Triton solution (Sigma Aldrich, St Louis, MO), for 10 minutes at 
room temperature, in a humidified chamber. Cells were washed twice in PBS in glass 
histological wash containers, each for 5 minutes.  
  Slides were blocked with a 5% normal goat serum (NGS) solution of PBS, 
(Vector Laboratories, Burlingame, California), for 15 minutes. Goat serum, like serum 
from all species, contains all the protein components of blood – including albumin, which 
reduces nonspecific antibody binding by ‘collecting’ the majority of proteinaceous 
material in the sample.  
 Slides were then incubated for two hours in a humidified chamber with primary 
antibody against SV40 Large T antigen (SV40 T Ag v-300, Santa Cruz Biotechnologies, 
Inc, Santa Cruz, CA), at a concentration of 1:200 in 5% NGS, at room temperature. 
Primary antibody was then tapped off onto a paper towel, and slides were washed in wash 
buffer and PBS, for 5 minutes each, to remove background staining. Slides were rinsed a 
final time in ddH20, mounted using Vectashield with DAPI (DAPI is commonly used as a 
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nuclear stain; Vector Laboratories, Burlingame, CA), and then imaged using a 
Fluorescent microscope. Positive DAPI and Large T antigen counts per field were 
determined using the computer program ImageJ. This program detected point maxima in 
DAPI- and Large T-stained cells  (‘Process’ à ‘Find Maxima..’ à ‘Tolerance = 28’). 
Each point is assumed to represent a unique positive staining event.   
  
  Spectrophotometer Absorbency Reading 
 
Absorbency readings at various wavelengths can provide specific information 
about the concentration of certain compounds in a solution. Because double-stranded 
DNA absorbs UV light at 260 nm, and protein contamination can be approximated via 
absorbance at 280 nm, we calculated the ratio of these two absorbencies using a 
spectrophotometer (Nanodrop ND-1000 Spectrophotometer, Thermo Fisher Scientific, 
Waltham, MA; (73)).  
 Extracted DNA samples were thawed to room temperature and 10 µL was 
aliquoted into separate labelled microcentrifuge tubes, along with a 10 µL aliquot of the 
elution buffer used in the extraction itself, AE buffer (Qiagen). These aliquots were then 
brought to the spectrophotometer for analysis; the remaining volume of extracted DNA 
was returned to the -20°C freezer for storage.  
 The device was first ‘cleared’ by loading and analyzing a 2 µL sample of 
ultrapure deionized water (Invitrogen, Life Technologies, Bedford, MA). Next, 
background signal was minimized by ‘blanking’ the machine with 2 µL of AE buffer, the 
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solvent into which samples were extracted. Between each sample reading, all surfaces 
that had liquid were blotted dry with a KimWipe (Kimberley-Clark Professional, Irving, 
TX), wiped with deionized water on a second KimWipe, and vigorously rubbed dry. 
Measurements across all BEZ-235 concentrations were repeated in triplicate. 
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RESULTS 
Observational Data 
 
One important observation made while analyzing cell growth during BEZ-235 
incubation, was that in many of the 1000nM wells, and to a much lesser degree in 100nM 
and 10nM wells, small crystalloid fragments were observable via light microscopy. These 
fragments were not visible in 0nM wells, and were non-adherent and present in multiple 
focal planes, making it likely that BEZ-235 had precipitated out of solution. Further 
experimentation using 1000nM solutions revealed that they were present in higher 
numbers in certain liquids than others (double distilled H20 > K-10 media > PBS; data not 
shown). Collectively, these data suggest that 1000nM is not an appropriate physiological 
dose, and that results from this experimental condition should be interpreted with caution.  
 
MTT Assay  
 
 The results of the MTT cell viability assay were as follows:  
 
	  56 
 
 
Figure 16. MTT CCD-1105 cytotoxicity assay performed in a 96-well 
plate following 48 hours of BEZ-235 pretreatment and ‘mock’ viral 
infection protocol conditions (100µL of media alone was used), as 
outlined in Figure 14. Cells were initially plated at 4,900 cells/well. 
Values shown are the averaged difference in absorbance readings 
(570nm–630 nm) of wells plated in triplicate, across all treatment 
conditions, with standard error bars shown. A set of ‘blank’ wells, 
containing MTT alone and no cellular component, were included. Three 
wells were also pre-treated with 3% formaldehyde, 20 minutes prior to 
MTT addition, to induce cell death as a positive control condition.  All 
treatment conditions are not significantly different (one-way ANOVA, p > 
.05; analysis not shown).  
 
Efforts to replicate identical conditions in the MTT assay protocol to those of the 
experimental time-course were stymied by technical limitations. The spectrophotometer 
(SpectraMax 384Plus, Molecular Devices) was only able to read 96- or 384-well plates, 
not the 6 well plates that were used for all experimental assays. This represents a small 
but necessary deviation from an exact replication of the protocols of the ‘master’ 
experimental time-course. The number of cells plated was scaled down according to the 
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ratio of each plate’s surface area, to preempt cellular overcrowding: [9.4 cm2]:[.32 cm2] 
gives a numerical ratio of ~30x. Thus, the original cell population of 50,000, plated in 6-
well plates, was reduced to (50,000/30) = ~1,700 cells per well for plating into 96-well 
plates.  
 
Quantitative PCR 
 
 qPCR analysis revealed variable and somewhat inconclusive results, when 
probing for a relationship between BK viral copy number and BEZ-235 drug treatment 
concentration (Table 2; Figure 17). qPCR analysis was conducted as described above, 
and  BKV copies/PCR reaction were calculated (‘#’ in Table 2). This information was 
then correlated with the mass of total DNA loaded per reaction via spectrophotometer 
analysis at 230nm, in order to calculate copies BKV/ug DNA (see Table 2). Results are 
shown graphically across BEZ treatment conditions in Figure 17.  
  
Table 2. Tabulated values for quantitative PCR and 
spectrophotometer assays, showing calculation of copies BKV/µg 
DNA. ‘#’ represents ‘raw’ numerical data produced after PCR 
amplification of VP-1 specific sequences of BEZ-235 treated cell 
populations. Because 20 µL of sample were added to each PCR reaction 
well, BKV copies/µL column was calculated by dividing ‘#’ by 20. ‘*’ 
represents raw spectrophotometer readings, reflecting the measured 
concentration of all DNA (host cell and BK viral), in ng/µL. Dividing this 
column’s values by BKV copies/µL results in the cancellation of µL, and 
gives copies BKV/ ng DNA. The final column (far right) shows copies 
BKV/µg DNA; these values are shown graphically in Figure 17.  
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BEZ 
Concentrations 
viral 
copies/PCR 
reaction # 
viral 
copies/µL 
Ng 
DNA/ 
µL * 
Copies 
BK/ng 
DNA 
Copies 
BK/µg 
DNA 
0 nM 28100000 1405000 55.9 25138 25 
10 nM 4720000 236000 7.4 31827 32 
100 nM 11366667 568332 44.4 12809 13 
1000 nM 17066667 853332 6.9 123092 123 
 
 
 
 
Figure 17. Copies of BK virus per ug of total CCD-1105 DNA, across 
treatment with variable BEZ-235 concentrations. Ratios were 
calculated using primers specific for BKV VP1, in a quantitative (‘real-
time’) Fluorescent PCR assay. These concentrations spanned a relatively 
wide range: 0, 10, 100 and 1000 nM.  
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Western Blot Assays 
   
In Western blotting, it is standard to include a ‘loading control’ assay for each 
experimentally assayed protein. Usually, loading control proteins are present ubiquitously 
in the intracellular environment of most cell types, such as the cytoskeletal proteins actin 
or tubulin. A similar loading control signal across wells ensures that one well was not 
loaded with more sample than the others. 
When possible, we sought to measure the phosphorylation status of mTOR 
pathway proteins as a function of their total concentrations in the cell. Thus, rather than 
use a ‘standard’ loading control protein such as tubulin or actin, for the Akt-Ser473 assay, 
a pan-Akt antibody was used (Figure 18).  
Antibodies used in mTOR pathway Western blotting were chosen for the 
functional significance of the residues that they were specific for. Full Akt kinase activity 
occurs when both serine 473 and threonine 308 are phosphorylated, although the relative 
importance of each site is a subject of debate (74). A key phosphorylation site on mTOR 
is at residue serine 2448, which is the phosphorylation site that activated Akt indirectly 
upregulates (via decreased PRAS40/TSC2 phosphatase activity) (75). Phosphorylation of 
all of these residues represents a dynamic equlibrium between phosphatases tending to 
reduce phosphorylation, and kinases tending to promote phosphorylation. We examined 
the status of these mTOR pathway markers via Western blotting, in both the presence and 
absence of BK infection. In BKV-infected cells (MOI=1.0), we saw a dose-dependent 
decrease in Akt Ser-473 phosphorylation, indicating decreased Akt activity (Figure 18). 
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Furthermore, a strong trend of decreased BK Large-T antigen expression was seen with 
increasing concentrations of BEZ-235 pretreatment (Figure 19).  A weaker trend of 
decreased mTOR phosphorylation at serine residue 2448 was observed in non-virally 
infected cells (Figure 20). The implications of these results will be discussed below.  
 
 
 
Figure 18. Treatment of BK-infected CCD-1105 cells with the dual 
PI3K/mTOR inhibitor BEZ-235 reduces activation of the mTOR 
intermediate Akt, as measured by phosphorylation at the Serine-473 
phosphorylation (Akt MW is 60kD). SV-40 (strain 776; provided by X. 
Dang) was used as a positive control. The ladder did not visualize upon 
film development, but was visible on the undeveloped membrane itself. 
The two images were superimposed and the ladder was drawn on the film 
in sharpie, to assist in sample size identification.  
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Figure 19. Treatment of BK-infected CCD-1105 cells with the dual 
PI3K/mTOR inhibitor BEZ-235 reduces efficiency of BKV viral 
replication, as measured by Large T antigen expression. BK Large T 
antigen expression (MW 90kD, cross-reactive with the primary antibody 
used in this assay, SV40 Large T antigen) was measured against basal 
levels of Akt (pan-Akt; MW 60kD). SV-40-infected cells (strain 776; 
provided by X. Dang) were used as a positive control. 
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Figure 20. Treatment of non-infected CCD-1105 cells with increasing 
concentrations of the dual PI3K/mTOR inhibitor BEZ-235 modestly 
reduces the phosphorylation of mTOR at residue serine 2448 (MW is 
249kD). α-tubulin (40kD) was used as a loading control. 
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Fluorescent Immunohistochemical Analyses  
 
 Fluorescent immunohistochemical staining analyses of BK Large T antigen and 
DAPI expression in BKV infected cells showed promising results. A preliminary visual 
inspection of randomized fields of view in each of the treatment conditions appeared to 
show a net decrease in the number of infected cells, when compared to the total number 
of cells per image (i.e. both productively and nonproductively infected; Figure 21).  
These visual observations were confirmed by a quantitative analysis (Figure 22). The 
‘raw’ positive counts across conditions, used to generate Figure 22, are shown in Table 3.  
 
 
Figure 21. Representative immunohistochemical staining images 
across five BEZ-235 concentrations: 0 nM, 10 nM, 100 nM and 1000 
nM. Also included was an identical well infected with SV40 as a positive 
control to account for use of SV40 Large T polyclonal antibody (Santa 
Cruz Biotechnologies, Dallas, TX). DAPI/Large T images taken from an 
identical field of view via Fluorescent microscopy at 200x magnification. 
Scale bars represent 50 µm.  
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Table 3. Positive counts of A) DAPI- and B) Large T-antigen stained, 
BKV-infected, CCD-1105 cells. Counts were tallied per field of view of 
(200x magnification), and averaged over five randomized images per 
treatment condition. Images were analyzed visually for Large T antigen 
stained images, and using ImageJ (NIH) for DAPI-stained images. Green 
boxes contain averaged values; ‘SV40’ column contains cells infected 
with SV40 rather than BKV. Calculations for standard deviation and 
standard error are also shown.  
 
A) DAPI Positive Counts Condition    BEZ235     
            Image # SV40 0nM 10nM 100nM 1000nM 
1 446 599 295 574 61 
2 520 679 393 494 313 
3 402 469 433 588 480 
4 497 502 326 43 124 
5 450 512 343 424 473 
AVERAGE 463 552.2 358 424.6 290.2 
STDEV 46.3 85.6 54.9 223.3 193.7 
STERROR 20.7 38.3 24.6 99.9 86.6 
      B) Large T antigen Positive Counts Condition              BEZ235 
 
 
           Image # SV40 0nM  10nM 100nM 1000nM 
1 40 25 0 2 2 
2 13 4 4 2 1 
3 18 23 9 0 0 
4 28 29 3 0 0 
5 5 5 13 0 1 
AVERAGE 20.8 17.2 5.8 0.8 0.8 
STDEV 13.6 11.8 5.2 1.1 0.8 
STERROR 6.1 5.3 2.3 0.5 0.4 
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Figure 22. Percentage of BK Large T-Positive nuclei to DAPI-positive 
nuclei in immunohistochemical staining assay of BKV-infected CCD-
1105 cells (values taken from green-colored cells in Tables 3A and B), 
with 48-hour BEZ-235 treatment at the indicated concentrations.  
Ratios reflect averaged values of sets of five randomized slide images 
(shown in Table 3 above), at 200x magnification. Two identical trials of 
the IHC were performed, with similar quantitative results (data not 
shown).  Bars with ovals indicate statistically significant differences (one-
way ANOVA; ‘o’ indicates p<.05).   
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DISCUSSION 
The goal of this project was to quantify the effects of the mTOR pathway 
inhibitor BEZ-235 on BK viral replication, using three separate biochemical approaches. 
By having each assay substantiate and confirm the results of the others, rather relying 
only on the strengths (and weaknesses) of a single assay, the hope was that we would be 
more certain of the effect of this compound on virally infected CCD-1105 cells.  
The combined results of these three sets of assays, particularly the Western blot 
examining Akt Serine-473 phosphorylation status, suggest that BEZ-325 effectively 
reduces mTOR pathway activity in a reproducible manner. This is consistent with what 
past studies have demonstrated using this drug in similar cell lines, as well as being its 
pharmacological raison d'être.  
The reality, however, is that regardless of how efficiently BEZ-235 down-
regulates the mTOR pathway in uninfected host cells, the result of its effects on mTOR 
pathway activity is much more nuanced in BKV-infected cells. The ‘net outcome’ in such 
experimental conditions is likely dependent on the summation of BEZ-235-induced 
downregulation and BKV-induced upregulation of this signaling pathway. Other 
potentially relevant factors that may regulate the observed activity of the mTOR pathway 
include the number of virions added per well, the host cell density (see qPCR discussion 
for further details), BEZ-235 metabolism and pharmacokinetics, and the duration of 
BEZ-235 treatment. Regarding the effect of the duration of drug treatment, it was unclear 
whether 48 hours was sufficient to promote adequate mTOR down-regulation. Should 
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BEZ-235 have been added after viral infection for a further 48 hours? Further work will 
be required to address this question.  
Given the observed BEZ-235 precipitation in 1000nM wells, it was likely that the 
range of BEZ-235 concentrations tested was broader than necessary. Given that BEZ-
235’s IC50 (concentration at which 50% of the indicated enzyme activity is abolished) is 
~4 nM for PI3Kα, and 20.7 nM for mTOR itself, further studies should perhaps use BEZ-
235 concentrations closer to those levels (76). Nonetheless, our use of higher 
concentrations of BEZ-235 on intact cells was a reflection of the fact that the EC50 of this 
drug for inhibition of mTOR signaling is clearly higher than the IC50 observed when 
examining effects on purified enzyme. 
Of note is that mTOR inhibition, of any potency, does not interfere with BK viral 
entry into the host cell. BEZ-235 does not block BKV binding to ganglioside host cell 
receptors, nor does it affect any step in BKV vesicular trafficking to the host cell nucleus, 
for that matter. As such, the rate of viral entry across all BEZ-235 assays can be 
presumed to be equal. The results of MTT assays indicate that there is likely little toxicity 
within the range of BEZ-235 concentrations tested. However, given the differential 
DAPI-positive cell counts during the IHC assay (see Table 3A), it is likely that BEZ-235 
may produce a cytostatic effect by reducing the rate at which cells progress through the 
cell cycle. 
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MTT Assay  
The conclusions that can be drawn from this cytotoxicity assay, shown in Figure 
16, are limited. It is clear, however, that because there are no significant differences 
across treatment conditions, the range of absorbance readings across all treatment 
conditions is similar, and BEZ-235 does not, at least in this assay, cause an observable 
cytotoxic effect at the concentrations and tested.  
Interestingly, the highest absorbance readings, which supposedly correspond to a 
larger quantity of ‘yellow’ MTT being reduced (metabolized) into ‘purple’ product by 
live host cells, were found in wells incubated with 10 nM BEZ-235 and 3% 
formaldehyde. This finding is the opposite of what might be expected, and contradicts the 
supposed cytotoxic nature of formaldehyde, which is commonly used as a cellular 
fixative.  
There are likely several confounding factors that influence the absorbency 
readings of the MTT assay. It is possible that, due to the small number of cells/well (10 – 
20,000 at the time of assay), relatively small quantities of MTT were metabolized and 
that the spectrophotometer lacks the sensitivity/resolution necessary to detect such small 
differences. Homogenization and resuspension of the solution after MTT metabolism 
produced air bubbles in virtually all wells. The presence of these air bubbles likely 
affected the accuracy of measurements across all drug concentrations, and may have 
produced the trends seen in Figure 16. Other potential factors affecting the results of this 
assay include the use of multiple aspiration steps (while BEZ-235 was added and 
removed, wash steps, etc) and the small number of cells (5,000) plated per treatment 
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condition. Given the sensitivity of this assay, loss of cells due to any cause could have a 
significant effect on the results.  
 
Quantitative PCR 
 
  qPCR Specificity 
 
 Quantitative PCR is an immensely powerful and specific technique. Theoretically, 
this assay can accurately detect minute variations in target sequence copy number – even 
between samples containing only 10 and 5 copies of a primer-specific sequence. 
However, equally important is the immense significance we are ascribing to this 
variation, as well as the assumptions we are making when using VP1 as a proxy for BK 
viral replication.  
Our approach was to examine BK VP1, a gene transcribed and translated late in 
the BK replication cycle, presumably produced only after the BK viral genome has 
reached the nucleus and has successfully expressed early genes such as Large T antigen. 
Upon observing lower levels of transcript for VP-1, we concluded that BEZ-235 
treatment had led to less efficient BK viral replication. Further studies are needed to 
validate the appropriateness of VP1 as a marker of replicative efficiency. What about the 
VP1 amplified from virion capsid coats that were not able to initiate a productive 
infection? What about those virions still contained in acidified vesicles, or in the process 
of engaging ERAD pathway machinery? An early step in the DNA extraction process is 
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cell lysis. This includes degradation of any and all cellular plasma membrane components 
– allowing for the pooling of productively and non-productively-infecting BK virions 
from nuclear, endosomal, and ER-associated compartments. If the experimental question 
to be addressed is what the effects of BEZ-235 are on production of infectious BK 
virions, these issues represent a potential source of error in the interpretation of qPCR 
results.  
Precisely because of the ability of qPCR to detect immensely small differences in 
copy number, human errors that introduce ‘massive’ variation in copy number become 
increasingly significant. Practically, what this means that the results produced during 
PCR analysis are just as likely due to ‘experimental error’ and accidental contamination, 
as they are to the intracellular effects of BEZ-235 on viral replicative efficiency.  
 
 Experimental Errors 
 
Experimental error in qPCR assays comes from many sources. One major source 
may have had to do with the viral infection protocol, which is common to all three of 
types of assays in this project. 
After counting a well to determine the correct number of BK virions to add to 
each well for an MOI of 1.0, this number of virions was then added to each of five 
separate glass tubes (one for each experimental well) containing 1 mL of media each (just 
enough liquid to cover the slide bottom, thus facilitating infection). After brief vortexing, 
the homogenized viral suspension was then pipetted into the wells. The original 
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reasoning was that having eight individual viral suspensions would allow for more 
accurate virion distribution to each of the wells. However, this was not the case.  
Unnecessary pipetting, especially of concentrated solutions, represents a potential 
source of error. Given that BKV was stored in aliquots of 2.5*106 virions per 54.9 uL 
(~45,537 virions per uL), the pipetting of even a single uL of suspension represents a 
huge number of infectious units in highly concentrated form. After accounting for the fact 
that a 10 uL pipette holding 2.31 uL of liquid might reasonably contain 2.29, or 2.34 uL 
of volume, it becomes easy to see how repeated pipetting steps could lead to increased 
variation in delivery volume. Pipettes are recalibrated each year for exactly this reason, 
but it is not unreasonable to assume some variation is unavoidable. This variation may 
have resulted in a broad range in the number of infectious units delivered to experimental 
samples, and consequently a range of infectious events that took place over the course of 
the experiment.  
Other error sources include: a) incomplete cellular homogenization or incubation 
with lysis buffer, such that not all genetic material was extracted from other cellular 
components (membranes, organelles, etc). CCD-1105 cells incubated at higher 
concentrations of BEZ-235 may be more susceptible to the lytic effects of the reagents 
contained in the lysis buffer. Another error source may have been the loss of cells via 
mechanical suction during any one of many aspiration steps (removal of media 
containing BEZ-235, removal of PBS washes, etc).  
Loss of cells via aspiration may partially explain the trend seen in the results seen 
in Figure 15. If we assume that increasing concentrations of BEZ-235 cause decreased 
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cell viability, via the decreased translation of attachment or adherence proteins, it is 
possible that the cell population incubated with 1000nM BEZ-235 could be relatively 
more sensitive to aspiration than cells incubated with lower concentrations. This may 
have resulted in a decrease in overall DNA content recovered from this treatment 
condition (a ‘decrease in the denominator’). The result might be a higher ratio of copies 
BKV/µg DNA, when perhaps the actual trend, given a constant mass of genetic material, 
is one of ‘constancy’ across all drug treatments.  
Finally these cell populations may have simply been overloaded with too much 
BK virus, thereby reducing any observable down-regulation of viral replication induced 
by BEZ-235. This is especially likely given the indirect mechanism of action of this drug 
in affecting BK viral replication. If we assume that BEZ-235 does appreciably down-
regulate mTOR pathway activity and results in decreased overall ribosomal biogenesis, 
just how much of an effect is this likely to have? What degree of decrease (in rate of 
ribosomal biogenesis, or percent reduction in ribosome number) is required to 
appreciably affect the rate of viral replication? Perhaps a reduction of the MOI from 1.0 
to .1, or .01, along with a prolonged BEZ-235 incubation time and more insight 
specifically into levels of ribosomes themselves, might allow us to further tease out 
answers to these questions. 
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  Potential Further Directions in qPCR Experimental Design 
 
As I realized only late in my project, the use of an internal qPCR control may 
have been helpful in discerning whether or not equal amounts of sample had been loaded 
into all reaction wells. An ‘internal’ control in this instance would involve adding a set of 
primers and probe specific for a host cell genomic DNA sequence, such as the genes 
encoding the cytoskeletal proteins actin or tubulin, or many other possible DNA 
sequences, whether they be within genes or non-transcribed regions of the human 
genome. Such an analysis would control for the effects of BEZ-235 on host cell 
proliferation or survival. An internal qPCR control for a host cell gene may have proven 
to be a more accurate way of insuring that we were actually comparing the number of BK 
virion genomes from equivalent numbers of host cells.   
Amplification of this gene would occur simultaneously with that of BK VP1, in a 
single PCR reaction well. Although separate standard curves would need to be generated 
and run for each gene amplification, it is likely that the inclusion of an internal control 
could provide an increase in experimental accuracy and scientific confidence in the PCR 
results generated. A second amplification curve, unaffected by the experimental 
condition, would allow for monitoring of inconsistent sample loading as a source of error. 
This would allow for more accurate determination of the effect of BEZ-235 on BK viral 
replicative efficiency.  
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Western Blot Assays 
 
Using Western blot assay were used to determine the activity levels of mTOR 
proteins at various levels of the pathway, notably by assaying mTOR and its upstream 
regulator Akt. Importantly, these proteins exist in roughly constant quantities in the 
intracellular environment; it is their ‘activation state’ (i.e. phosphorylation at particular 
known residues), rather than modification of the number of molecules, that up- or down-
regulates activity of the pathway as a whole. After all, signaling to increase transcription 
and translation of any protein may represent a large period of time on a cellular scale. 
This may have implications for the duration of BEZ-235 treatment in order to induce a 
decrease in the rate of ribosomal biogenesis. Further investigation of this phenomenon is 
needed.  
Western blotting represents the major investment of time and energy in this thesis 
project. Many electrophoresis and blotting assays (~9 total) were carried out, using 
samples from independent experimental time-courses representing ~150 hours of cell 
growth. Only a small number of these assays were of sufficient quality to be presented 
here. This is largely due to the significant number of optimizations and small adjustments 
that must be performed in order to produce a ‘clean’ blot – one that shows experimental 
information that is both clear (i.e. interpretable) and that investigates targets of interest.  
 From the outset, this project had three separate but related goals for the use of 
Western blot assays in the experimental BKV infection time-course described above 
(Figure 14). The first was a proof of concept; that BEZ-235 actually does, in fact, down-
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regulate the mTOR pathway specifically and potently in non-virally infected cells, as it 
has been shown to do by previous studies. Secondly, we aimed to show that BEZ-235 
induces a dose-dependent down-regulation of mTOR pathway intermediates in BK 
virally infected cells. Third, we sought to show that treatment with BEZ-235 reduced the 
replicative efficiency of BKV. ‘Replicative efficiency’ is not an easily defined viral 
attribute; thus we used the expression of a key BKV replicative protein expressed early in 
the replicative cycle, BK Large T antigen, as a proxy marker. 
 The results of Western blot experiments produced in this thesis project have 
answered some of these research questions to a greater degree of certainty than others. 
Staining for Akt Serine-473 phosphorylation in non-virally infected cells produced a 
dose-dependent decrease in band intensity that was reasonably strong, clear, and reliable 
(Figure 18). This is important because BEZ-235 does not directly inhibit Akt-
phosphorylation at this site; rather it inhibits PI3K activity, which mediates Akt 
phosphorylation through secondary signaling mechanisms (i.e. PIP3 and PDK-1). Perhaps 
the same is true for its direct inhibitory effect on mTOR (which we demonstrated weakly 
in Figure 20), and downstream effect on P70S6K (whose activity was not tested in this 
thesis project).  
 Perhaps most importantly, we showed a fairly clear decrease in BK Large T 
antigen band intensity with increasing concentration of BEZ-235 (Figure 19). This result 
is exciting; it supports the hypothesis that BEZ-235 inhibits or slows the rate of BK viral 
replication. However, it is also possible that Large T antigen band intensity was due to 
the fact that fewer CCD-1105 cells were present; i.e. as an artefact of the drug’s 
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cytostatic effect on cell growth. The pan-Akt loading control should show even amounts 
of cellular lysate loaded per well. In the SV40 Large T staining experiment, however,  
bands appeared to stain strongly – making analysis difficult.  
 
Potential Further Directions in Western Blot Experimental Design  
 
 We did not have sufficient time to test for levels of all significant mTOR pathway 
proteins, or begin to determine relationships in the setting of viral infection (for example, 
investigating the extent of positive or negative mTOR feedback activity in virally 
infected vs. non-infected cells). In particular, no assays were conducted looking at the 
downstream effectors of the mTOR pathway, 4EBP and P70S6K. The latter is the most 
direct regulator of the rate of ribosomal biogenesis and turnover in host cells, and thus 
needs to be investigated in the future.  
 
Immunohistochemistry Assays 
 
 While the trend in Large T expression seen in Figure 20 may seem visually 
appealing and indicative of a strong dose-dependent effect of BEZ-235 on Large T 
antigen expression, drawing conclusions from this visual evidence alone can be 
misleading. One important factor that was taken into account was the total number of 
CCD-1105 cells present in each field of view. It can be reasonably assumed that, all other 
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conditions held equal, fields with higher total number of CCD-1105 cells will also have 
higher counts of BKV-infected, large T antigen-expressing cells.  
 The total number of DAPI-stained cell nuclei per field were analyzed using the 
freeware program ImageJ. Earlier in the project, analysis of Large T antigen and DAPI 
expression was attempted with the freeware program CellProfiler (Broad Institute). This 
analysis stalled and was eventually discarded for use of ImageJ, when the CellProfiler 
program began labeling single nuclei as multiple objects. This led to vast discrepancies in 
cell counts, and an unacceptable level of inaccuracy in the total object counts that this 
program was reporting. Thus, analysis with CellProfiler was discontinued, in favor of 
ImageJ.  
  Final analysis with ImageJ showed DAPI-positive point maxima cell counts 
(found in Table 3) that substantially decrease as BEZ-235 concentration is increased, 
particularly at 1000nM BEZ-235. This may be indicative of BEZ-235 mediated reduction 
in cell growth; the drug may be affecting the length of time cells must remain in G1 
phase of the cell cycle in order to fully replicate all necessary host cell proteins before 
progressing to mitosis and cell division. By slowing the overall rate of host cell 
replication, BEZ-235 may have, after 48 hours of treatment, reduced the total number of 
cells available to be stained for DAPI. Further experiments are needed to substantiate this 
claim. One approach would be to examine the effect of BEZ-235 on critical cell cycle 
proteins such as cyclins or cyclin-dependent kinases (CDKs).   
Given that IC50 values for enzymes affected by this inhibitor are in the sub-50 nM 
range (see above), using this concentration for any assays (which represents more than 
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20x the useful range of this drug) is not a useful measure of physiologic conditions in a 
human kidney.  
 
 Sampling Bias in Immunohistochemical Imaging 
  
One major source of error in producing the cell counts for Large T and DAPI-
stained cells is sampling bias, which concerns systematic bias incurred during the process 
of images were captured. Images were selected ‘randomly’ for further analysis while 
scanning around the microscope. This randomization process was accomplished by brief  
‘blind rotation’ of the axes that held the slide in place: without looking into the 
microscope itself, or viewing the image as it appeared on the computer screen. Identical 
DAPI/Large T antigen screen captures were then taken at that location.  
A significant assumption involved in this method was that the averaged positive 
counts from these five images are representative of cell distributions across the entire 
chamber slide. The growing surface of each slide slide was relatively large (4cm2); thus 
five images per slide, at 200x magnification, cover only a tiny fraction of its total surface 
area. Large deviations from the ‘true’ average values, in even one of the five images, can 
significantly affect the averaged results, and the conclusions that can be drawn from 
them. It is likely that taking images at a lower magnification, covering a larger surface 
area and with more positive countable events per image field, could reduce the effects of 
sampling bias.  
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Concluding Remarks 
 
Collectively, the results of these assays have shown that there is promise in using 
BEZ-235 as a targeted antiviral agent against BK virus. As conclusive and reproducible 
qPCR analysis showing clear dose-dependent trends was lacking in this project, PCR data 
showing definitive reduction in viral genome number would be an important first step in 
further drug validation. Further testing and experimentation is needed to show the degree 
and sensitivity of BEZ-235 within the complete scope of human physiology, and how this 
drug affects viral replication itself, not just the proxy markers Large-T antigen or VP1. 
The development of an animal model of BK infection would greatly facilitate the 
discovery of answers to these questions.  
Regardless of whether or not BEZ-235 consistently and in actuality reduces viral 
replication in a cellular model of BKV infection, it is an entirely different question to ask 
whether it does so in an intact human kidney experiencing BK viral reactivation. 
Hopefully, a more systematic approach by researchers in the coming months or years will 
yield data convincing enough to see BEZ-235 through to clinical trials as a BK-specific 
peri-transplant antiviral agent.   
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